P68.10 PFN1 Induces Tumor Metastasis Through Promoting Secretion of Microvesicles By ROCK I/p-MLC Pathway in Non-Small Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1203
Author(s):  
Y. Wang ◽  
C. Hu ◽  
Y. Lu
Author(s):  
Haiping Xiao

Abstract Background Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Distant metastasis is thought to be one of the most important factors responsible for the failure of NSCLC therapy. MicroRNA-7-5p (miR-7-5p) has been demonstrated to be a tumor suppressor in breast cancer, hepatocarcinoma, prostate cancer and glioblastoma multiforme (GBM). However, its role in NSCLC is still not fully understood. This study evaluated the role of miR-7-5p in the progression of NSCLC and explored the underlying mechanism. Materials & methods The quantitative real-time PCR (qPCR), MTT, migration and invasion assays were used to evaluate the effects of miR-7-5p on the proliferation, migration and invasion of A549 and SPCA-1 cells. A tumor xenograft model was created to determine the effects of miR-7-5p on metastasis in vivo. The dual-luciferase reporter gene, neuro-oncological ventral antigen 2 (NOVA2) overexpression and western blotting assays were performed to explore the underlying mechanism. Results MiR-7-5p is downregulated in NSCLC tissues and lung cancer cell lines. It suppresses proliferation, migration, invasion and EMT marker expression in vitro and in vivo. Further study showed that miR-7-5p suppresses tumor metastasis of NSCLC by targeting NOVA2. Overexpression of NOVA2 attenuates the miR-7-5p-mediated inhibitory effect on lung cancer cells. Conclusion MiR-7-5p suppresses NSCLC metastasis. Targeting miR-7-5p may contribute to the success of NSCLC therapy.


PLoS ONE ◽  
2013 ◽  
Vol 8 (3) ◽  
pp. e59412 ◽  
Author(s):  
Nuo Xu ◽  
Deshui Jia ◽  
Wenfeng Chen ◽  
Hao Wang ◽  
Fanglei Liu ◽  
...  

Lung Cancer ◽  
2012 ◽  
Vol 77 (3) ◽  
pp. 585-592 ◽  
Author(s):  
Fang-Yi Lo ◽  
Hsiung-Ting Chen ◽  
Hung-Chi Cheng ◽  
Han-Shui Hsu ◽  
Yi-Ching Wang

2019 ◽  
Vol 374 (2) ◽  
pp. 304-314 ◽  
Author(s):  
Jing Li ◽  
Tao Yu ◽  
Mingxia Yan ◽  
Xiao Zhang ◽  
Li Liao ◽  
...  

2018 ◽  
Vol 25 (4) ◽  
pp. 1302-1317 ◽  
Author(s):  
Lingyu Li ◽  
Wei Li ◽  
Naifei Chen ◽  
Haixin Zhao ◽  
Guang Xu ◽  
...  

2021 ◽  
Vol 14 (4) ◽  
pp. 101039
Author(s):  
Zhiqiang Zha ◽  
Dailing Li ◽  
Peiling Zhang ◽  
Peipei Wang ◽  
Xisheng Fang ◽  
...  

2015 ◽  
Vol 30 (4) ◽  
pp. 359-363 ◽  
Author(s):  
Qunying Lin ◽  
Lei Xue ◽  
Tian Tian ◽  
Bo Zhang ◽  
Lijing Guo ◽  
...  

Objective To explore the prognostic value of serum interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) levels in patients with small cell lung cancer (SCLC). Materials and Methods IL-17 and VEGF levels were determined by a commercially available ELISA method. Results Serum IL-17 and VEGF levels were higher in the SCLC group than the control group (p<0.001 and p<0.0001, respectively). In addition, there was a significant correlation between IL-17 and VEGF. The level of IL-17 showed significant correlations with tumor stage and tumor metastasis, while serum VEGF levels were significantly associated only with tumor metastasis. Univariate and multivariate analysis indicated that an elevated IL-17 level was an independent prognostic factor for shorter overall survival in SCLC. Conclusions IL-17 may play an important role in tumor dissemination in SCLC patients and measurement of IL-17 could have useful prognostic value for worse overall survival in patients with SCLC.


Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 99801-99815 ◽  
Author(s):  
Shuai Zhang ◽  
Dehai Che ◽  
Fang Yang ◽  
Chunling Chi ◽  
Hongxue Meng ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document